CEO of Findacure
Dr Rick Thompsom joined Findacure in 2015 and has recently after been appointed CEO.
After completing his PhD in Evolutionary Biology at the University of Cambridge, he began as Head of Research, responsible for Findacure’s scientific projects, with the aim of developing a socially financed drug repurposing programme – Findacure’s rare disease drug repurposing social impact bond (RDDR SIB). Rick has designed and completed a proof of concept study to demonstrate the feasibility of the RDDR SIB to the NHS, investors, industry, and patient groups.
Rick also works to encourage industry engagement with rare disease patient groups, promoting an open and collaborative approach to rare disease research.